1. Home
  2. EYPT vs AIN Comparison

EYPT vs AIN Comparison

Compare EYPT & AIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.35

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$58.77

Market Cap

1.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYPT
AIN
Founded
1987
1895
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Textiles
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2005
1987

Fundamental Metrics

Financial Performance
Metric
EYPT
AIN
Price
$13.35
$58.77
Analyst Decision
Strong Buy
Hold
Analyst Count
4
4
Target Price
$28.75
$60.25
AVG Volume (30 Days)
1.1M
260.5K
Earning Date
03-04-2026
02-24-2026
Dividend Yield
N/A
1.91%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$42,339,000.00
$1,148,512,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$41.15
52 Week High
$19.11
$83.65

Technical Indicators

Market Signals
Indicator
EYPT
AIN
Relative Strength Index (RSI) 36.20 59.76
Support Level $12.11 $56.05
Resistance Level $13.68 $58.22
Average True Range (ATR) 0.99 1.47
MACD -0.28 -0.22
Stochastic Oscillator 23.16 70.73

Price Performance

Historical Comparison
EYPT
AIN

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

Share on Social Networks: